Andalus, a compound preparation for adult type 2 diabetes, is listed in China
jack_hua
发表于 2023-11-24 11:43:44
3642
0
0
AstraZeneca has recently announced the release of Andaishi& Reg; (Common name: Daggligin Metformin Sustained Release Tablets) This compound preparation for type 2 diabetes is marketed in China. It is reported that, as the only compound preparation of SGLT2 inhibitor and metformin hydrochloride sustained-release agent that takes a fixed dose once a day in China, daggligin metformin sustained-release tablets provide a first-line treatment option for improving blood glucose control in patients with type 2 diabetes.
The Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 Edition) points out that the short-term goal of diabetes treatment is to eliminate the symptoms of diabetes and prevent acute complications by controlling hyperglycemia and metabolic disorders, and the long-term goal is to prevent cardiorenal complications, improve the quality of life of patients and extend life through good metabolic control.
Professor Ji Linong, from Peking University People's Hospital, said that the arrival of daggligin metformin sustained-release tablets provided a new treatment method of "one scheme, double protection" for the achievement of short-term and long-term goals of diabetes treatment.
Professor Zou Dajin from Tongren Hospital affiliated with Shanghai Jiao Tong University School of Medicine believes that the two complementary mechanisms of action of Daggliflozin metformin sustained-release tablets help simplify treatment plans and improve patient treatment compliance.
Lai Minglong, general manager of AstraZeneca China, said that improving blood glucose control rate and reducing heart and kidney complications are important tasks for the prevention and treatment of diabetes in China, and hoped that the application of daggligin metformin sustained-release tablets would be accelerated in China.
Wen/Guangzhou Daily · New Flower City Reporter Tu Duanyu
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Lilly is reported to have reached a cooperation agreement with two pharmaceutical companies regarding the filling of injection pens
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion yuan in the expansion project of sterile preparations in Tianjin
- 4 billion yuan! Novo Nordisk launches aseptic formulation expansion project
- The world's first weekly insulin preparation has encountered setbacks in the United States, and the FDA requires additional information, with no hope of approval this year
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏
-
【ナスダック中国金龍指数は1%下落した。人気の中概株の多くは下落した】現地時間11月21日、ナスダック中国金龍指数は1%下落し、人気の中概株の多くは下落し、必死に10%超下落し、愛奇芸は7%超下落し、百度は6%近く ...
- 比尔992
- 昨天 11:57
- 支持
- 反对
- 回复
- 收藏